𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease

✍ Scribed by Rafael Rodríguez-Puertas; Julio Pascual; Teresa Vilaró; Ángel Pazos


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
156 KB
Volume
26
Category
Article
ISSN
0887-4476

No coin nor oath required. For personal study only.

✦ Synopsis


We studied the autoradiographic densities of all pharmacologically characterised muscarinic receptors (MR) in frontal, temporal, and visual cortex, hippocampal formation, and striatum in autopsied brains from 19 histopathologically verified patients of Alzheimer's disease (AD) and in matched controls. Almost all (16 of 19) of the AD cases were severe. In AD brains, total MR, M1, and M3 MR subtypes were found to be significantly decreased in entorhinal cortex and in most hippocampal strata. Total MR and M1 receptors were also significantly reduced in visual area and in frontal cortex of AD brains, respectively. M2 receptors were significantly reduced over hippocampal formation but increased significantly in striatum of AD brains as compared with controls. M3 receptors in AD were in the range of controls in neocortex and striatum, whereas the M4 receptor subtype was also preserved in all brain regions in AD brains when compared with controls. This is the first autoradiographic study analysing the distribution of all MR subtypes in AD brains. These changes in MR densities concur with the general pattern of neuronal degeneration occurring in AD brains and partly explain the poor response of AD cognitive decline to present cholinergic supplementation therapies. Although M3 and M4 MR were labelled with nonselective approaches, the preservation of M4 and to a lesser degree M3 MR subtypes in AD brains could open an alternative way for the symptomatic therapy of AD dementia.


📜 SIMILAR VOLUMES


Development of M1 subtype selective musc
✍ R.D. Schwarz; M.J. Callahan; R.E. Davis; J.C. Jaen; H. Tecle 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

Clinical trials in Alzheimer's disease (AD) with first generation muscarinic agonists (e.g., arecoline, oxotremorine, pilocarpine) produced inconsistent results due to poor pharmacokinetic properties and a lack of separation between central and peripheral activities observed with these compounds. Se

Pharmacological in vitro characterizatio
✍ Eddi Meier; Kristen Frederiksen; Mogens Nielsen; Hanne Løve Lembøl; Henrik Peder 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB

The arecoline bioisostere, Lu 25-109-T, displays a pharmacological profile of a partial muscarinic agonist with a several-fold higher affinity for cortical M 1 receptors than for brain stem M 2 receptors and salivary glands M 3 receptors. The compound is selective for muscarinic receptors as it show